SGLT2 Inhibitors are sodium-glucose transport protein inhibitors that block glucose from being absorbed by the kidneys and instead be excreted through urine. They are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. SGLT2 Inhibitors are not approved for the treatment of Type 1 diabetes mellitus.
Invokana was approved by the FDA in March 2013 and was the first SGLT2 Inhibitor to be marketed in the United States. It is manufactured and distributed by Janssen Pharmaceuticals, a wholly owned subsidiary of Johnson & Johnson. Invokana is the market leader of the SGLT2 Inhibitor class, has been a blockbuster drug since its introduction to the market and has continued to increase market share for treatment of Type 2 diabetes mellitus.
On May 15, 2015, the FDA announced that SGLT2 inhibitors may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones. Ketoacidosis requires hospitalization and can cause fatal swelling of the brain known as cerebral edema, pulmonary edema, cardiac dysrhythmia, nonspecific myocardial injury, myocardial infarction, cerebrovascular accident, diabetic retinopathy, hypoglycemia, hypokalemia, severe dehydration and coma.
Formed in 2015, the SGLT2 Inhibitor Litigation Group educates litigation group members about ongoing federal and state litigation against the manufacturers of SGLT2 Inhibitors. The SGLT2 Inhibitor Litigation Group allows members to collaborate and coordinate regarding all aspects of the ongoing litigation and assist litigation group members by sharing pleadings, discussing favorable potential venues, developing the science and experts necessary for successful litigation, and sharing discovery obtained through the litigation.
The Group hosts meetings at the AAJ Annual and Winter Conventions and provides tools and resources for members to successfully litigate their cases. Group members network and discuss legal issues and strategies on the Group's plaintiff-only list server and at regular meetings, including AAJ Conventions and Education seminars.